Gilead allows 7 cos to sell hepatitis C drug

Subscribe to GoodReturns
US-based drug maker Gilead Sciences on Monday announced that it has provided license of its hepatitis C drug called 'Sovaldi generic' to seven companies to make and sell the drug in 91 developing countries including India, as per the Reuters report.

The companies which receive license for the medicine includes Cipla Ltd, Ranbaxy Laboratories Ltd, Cadila Healthcare, Mylan Laboratories Ltd, Sequent Scientific Ltd, Strides Arcolab Ltd and Hetero Drugs Ltd.

Meanwhile, Gilead allowed companies to fix their own selling price for the medicine but on the otherhand they will have to pay a royalty on their earned sales to Gilead.

Story first published: Monday, September 15, 2014, 23:00 [IST]
Please Wait while comments are loading...
Company Search
Enter the first few characters of the company's name or the NSE symbol or BSE code and click 'Go'